Biocompatibility of Coronary Stents
Related Experiment Video
Updated: Feb 25, 2026
Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
Published on: March 5, 2020
Thamarasee M Jeewandara1,2, Steven G Wise3,4,5, Martin K C Ng6,7
1The Heart Research Institute, Sydney NSW 2042, Australia. thamarasee.jeewandara@hri.org.au.
Insights
Coronary stents, including drug-eluting stents (DES), have improved treatment for coronary artery disease (CAD). However, they remain incompatible with blood vessels, necessitating research into truly biocompatible implants.
Area of Science:
- Cardiovascular Medicine
- Biomaterials Science
- Interventional Cardiology
Background:
- Coronary artery disease (CAD) is a leading cause of death globally.
- Coronary stents are crucial for percutaneous coronary revascularization, evolving from bare metal to drug-eluting stents (DES).
- First-generation DES reduced restenosis but introduced risks like delayed healing and late stent thrombosis.
Purpose of the Study:
- To review the evolution of coronary stents.
- To detail improvements aimed at reducing thrombosis and restenosis.
- To highlight research toward creating biocompatible coronary implants.
Main Methods:
- Literature review of coronary stent development.
- Analysis of incremental improvements in stent technology.
- Discussion of current research and future directions in coronary implant design.
Main Results:
- Stent development has progressed from bare metal to advanced DES.
- DES have mitigated restenosis but pose challenges in healing and long-term thrombosis.
- A fundamental incompatibility between current stents and vasculature persists.
Conclusions:
- Coronary stents have advanced significantly but still present clinical complications.
- Addressing the inherent vascular incompatibility is critical for future stent design.
- Research is focusing on developing truly biocompatible coronary implants.
Abstract:
Cardiovascular disease is the dominant cause of mortality in developed countries, with coronary artery disease (CAD) a predominant contributor. The development of stents to treat CAD was a significant innovation, facilitating effective percutaneous coronary revascularization. Coronary stents have evolved from bare metal compositions, to incorporate advances in pharmacological therapy in what are now known as drug eluting stents (DES). Deployment of a stent overcomes some limitations of balloon angioplasty alone, but provides an acute stimulus for thrombus formation and promotes neointimal hyperplasia. First generation DES effectively reduced in-stent restenosis, but profoundly delay healing and are susceptible to late stent thrombosis, leading to significant clinical complications in the long term. This review characterizes the development of coronary stents, detailing the incremental improvements, which aim to attenuate the major clinical complications of thrombosis and restenosis. Despite these enhancements, coronary stents remain fundamentally incompatible with the vasculature, an issue which has largely gone unaddressed. We highlight the latest modifications and research directions that promise to more holistically design coronary implants that are truly biocompatible.
